Paediatric drug development of ramipril reformulation, in vitro and in vivo evaluation by Russell, Craig et al.
Strathprints Institutional Repository
Russell, Craig and Begum, Sumyra and Hussain, Yasar and Hussain, 
Majad and Huen, David and Rahman, Ayesha S. and Perrie, Yvonne and 
Mohammed, Afzal R. (2015) Paediatric drug development of ramipril 
reformulation, in vitro and in vivo evaluation. Journal of Drug Targeting, 
23 (9). pp. 854-863. ISSN 1061-186X , 
http://dx.doi.org/10.3109/1061186X.2015.1036275
This version is available at http://strathprints.strath.ac.uk/56756/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
Paediatric Drug Development of Ramipril: Reformulation, In Vitro and In Vivo Evaluation. 
1Craig Russell, 3Sumyra Begum, 3Yasar Hussain, 3Majad Hussain, 2aDavid Huen, 2bAyesha S Rahman, 
1Yvonne Perrie and 1*Afzal R Mohammed 
1Aston School of Pharmacy, Aston University, Birmingham, UK. B4 7ET 
2a School of Biology, Chemistry and Forensic Science, University of Wolverhampton, UK, WV1 1LY 
2b
 School of Pharmacy University of Wolverhampton, UK, WV1 1LY 
3Pharmaspec Ltd, Birmingham, B8 1BZ 
 
 
* Corresponding Author:  
Afzal R Mohammed 
Email: a.u.r.mohammed@aston.ac.uk 
Phone: 0121-204 4183 
 
 
 
 
 
 
 
 
 
Abstract 
  
Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality 
following heart attacks in patients who develop indications of congestive heart failure. In the 
paediatric population it is used most commonly for the treatment of heart failure, hypertension 
in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid formulation, 
the current study evaluates the development of a range of oral liquid formulations of ramipril 
along with their in vitro and in vivo absorption studies. Three different formulation development 
approaches were studied: solubilisation using acetic acid as a co-solvent, complexation with 
hydroxypropyl-ȕ-cyclodextrin (HP-ȕ-CD) and suspension development using xanthan gum. 
Systematic optimisation of formulation parameters for the different strategies resulted in the 
development of products stable for twelve months at long term stability conditions. In vivo 
evaluation showed CMAX of 10.48 µg/mL for co-solvent, 13.04µg/ml for the suspension and 
29.58µg/mL for the cyclodextrin based ramipril solution. Interestingly, both ramipril solution 
(co-solvent) and the suspension showed a TMAX of 2.5h, however, cyclodextrin based ramipril 
produced TMAX at 0.75h following administration.  The results presented in this study provide 
translatable products for oral liquid ramipril which offer preferential paediatric use over existing 
alternatives. 
 
 
 
 
 
 
 
Introduction 
 Ramipril is used mainly in the treatment of mild to severe hypertension as well as to 
reduce the incidence of fatality following heart attacks in patients who develop indications of 
congestive heart failure. It may also be used to slow the progression of kidney disease in 
patients who suffer from high blood pressure in conditions such as diabetes,(1±3) 
microalbuminuria (albumin in the urine) or nephropathy. (2,3) Once administered, maximum 
absorption is approximately 50-60%(4) through solute transporters in the small intestine.(5) In 
the paediatric population, ramipril is used most commonly for the treatment of heart failure, 
hypertension in children with type 1 diabetes and also in the treatment of diabetic 
nephropathy.(6) 
 Solid oral dosage forms are the preferred method of administration for the general 
population. These however are often difficult or impossible for paediatric patients to swallow 
safely. (7) The preferred dosage forms for children include oral solutions, syrups, suspensions, 
and drops due to their wider acceptability and dose flexibility. Additionally, liquid forms of 
medication may also be administered by oral feeding tube when required. (8) Dose volume is 
a critical factor to consider during formulation development as the typical target dose volumes 
for paediatric liquid formulations DUHPO IRUFKLOGUHQ\RXQJHU WKDQ\HDUVDQGPO IRU
children 5 years and older.  
 During formulation, the physiochemical properties of the drug governs the route of 
formulation with solubility, pKa, and palatability being primary concerns. Careful excipient 
selection is imperative when targeting paediatrics to achieve the desired formulation effect 
whilst still accommodating the highly sensitive nature of the patient segment. The European 
Medicines Agency (EMEA) acknowledges that there may be no single formulation which 
meets all requirements for all paediatric age groups but dosage forms containing minimal 
number and quantities of excipients which offer dose flexibility and cheaper cost of production 
are preferred (EMEA/CHMP/PEG/194810/2005).(9)       
 Ramipril is commercially available as tablets, capsules and oral solution. However, the 
oral liquid is not prescribed for paediatric population owing to the reported toxicity implications 
associated with the use of high concentration of propylene glycol (E1520) within the 
formulation (EMEA/CHMP/PEG/194810/2005). (11) Research into the production of an age 
appropriate dosage form targeting paediatrics, was considered a priority as communicated in 
the revised priority list for studies into off-patent paediatric medicinal products 
(EMA/480197/2010).(10)  
 The current study aims to develop oral liquid formulations of ramipril which offers target 
pharmaceutical product profile (TPPP) comprising of small dose volume (not more than 5 mL 
to deliver 5mg, which is the common dose in children), long term stability, reduced dosing 
frequency (related to dose volume), flexibility for dose manipulation and evidence of 
biopharmaceutical performance. Three different strategies which included two solution based 
and one suspension based formulation approaches that meet the TPPP were investigated. 
Solubilisation of ramipril was studied using  acetic acid as a co-solvent and through 
complexation  with hydroxypropyl-ȕ-cyclodextrin (HP-ȕ-CD) whereas suspension was 
formulated using hydrophilic suspending agent. 
 Acetic acid was selected for use as a co-solvent in the solubilisation of ramipril as it 
dissolves the drug freely and is Generally Recognised as Safe (GRAS).  Similarly, HP-ȕ-CD 
(PRGLILHG ȕ-CD) was used for drug complexation as it offers improved solubility when 
compared to the parent molecule which would result in a linear relationship between the 
improvement in apparent solubility (drug) with increasing cyclodextrin concentration. Although 
parenteral administration of beta cyclodextrins may lead to nephrotoxicity, oral delivery is 
considered safe due to their low bioavailability (<1%).(12)  
 The formulation of oral suspension of ramipril was studied using xanthan gum as the 
suspending agent due to its pseudoplastic properties and solubility in water. Additionally, 
xanthan gum is suitable for use in a wide range of pH (between 3-12) which has benefits over 
hydrophobic polymers such as ethylcellulose which are sensitive to acidic conditions (as 
ramipril is most stable in an acidic environment) and require heating and cooling cycles to 
achieve solubilisation.  
 Following formulation development, stability testing was carried out to ensure that the 
formulations achieved the long term stability requirement listed in the TPPP. 
Biopharmaceutical performance of the dosage forms was evaluated and included the 
measurement of drug permeability using cell culture models followed by in vivo assessment 
in rats to determine the pharmacokinetic profile. Previous work has reported a correlation of 
R2=0.88 for drug absorption between humans and rats. (13) Similarly, drug absorption studies 
in the small intestine of humans and rats showed a linear correlation (R2=0.8) for both passive 
and carrier mediated absorption pathways. (14)  
 
Materials  
 Ramipril was purchased from Discovery Fine Chemicals (UK). Solvents for HPLC were 
supplied by Fisher Scientific (UK). Xantural® was purchased from Azelis (UK). All other 
reagents including HP-ȕ-CD, NaOH, HCl, Tween 20, 40, 60 and 80, Span 20, 40, 60 and 80 
and tissue culture media items were obtained from Sigma (UK) Ltd. Gibco Invitrogen (UK) 
supplied Hanks Balanced Salt Solution (HBSS) for tissue culture use.  
Methods 
HPLC method for the detection of ramipril 
 A Dionex GP50 Gradient Pump coupled to a Dionex UVD170U detector and a Dionex 
A550 auto sampler was used for HPLC studies. Perchlorate Buffer and Acetonitrile (55:45) 
was used as the mobile phase and the stationary phase was a C18 reverse phase column 
(150 x 4.5mm with 5µm Particle Size) with a flow rate of 1mL/min at a detection wavelength 
of 216nm. The injection volume was 50µl and the run time was 10 minutes (min). Calibration 
standards were produced via serial dilution in methanol and acetonitrile (Diluent A) (50:50). 
The standards were then diluted 1:5 in diluent B (water and acetonitrile, 45:55). The method 
was validated following the guidelines from International Conference on Harmonisation (ICH) 
(ICH Topic Q 2 (R1) 1995).(15) 
Method for particle size analysis 
 Particle size for suspensions was measured using Sympatec Helos (UK) particle sizer. 
)RUWKHPHDVXUHPHQWVRIVL]Hȝ/RIDVDPSOHZDVSLSHWWHGLQWRDJODVVTXDUW]FXYHWWHD
signal of at least 15% scattering was required for an adequate reading). Three measurements 
were taken for each formulation and an average result obtained for size and polydispersity.  
Method for zeta potential analysis 
 Zeta potential was analysed using a Brookhaven zeta potential analyser in conjunction 
with a BI-ZEL electrode assembly (Brookhaven Instruments). A 1:10 dilution was made of 
each formulation in distilled water to bring detection levels into a readable range and placed 
into the zetasizer cuvette. Triplicate readings were taken from three batches for each 
formulation and the mean value reported. 
Co-solvent approach to the solubilisation of ramipril 
 Acetic acid solutions were produced at concentrations of 4%, 3%, 2%, 1%, 0.5%, 0.1%, 
0.05%, 0.04%, 0.03%, 0.02% and 0.01% v/v. Ramipril was then added to each co solvent at 
0.01%w/v. The solutions were stirred for 1 hour (h) and filtered before HPLC to confirm 
complete solubilisation.  
 
 
Cyclodextrin Approach to the Solubilisation of Ramipril 
Phase solubility 
 Method described by Higuchi and Connors was used to investigate phase solubility of 
ramipril and HP-ȕ-CD complex.(16) This method was also adapted to assay the effect of 
temperature and pH on solubilisation. Six concentrations of cyclodextrin were produced in 
distilled water ranging between 1.2mM to 3.75µM using serial dilution. These were cooled to 
15°C and excess ramipril was added. Solutions were then maintained at this temperature for 
1h at which point a sample was taken, filtered and prepared for HPLC. This was repeated at 
30°C, 45°C, 60°C and 75°C. Similarly for pH, six concentrations of cyclodextrin were produced  
from 1.2mM down to 3.75µM using serial dilution. These were produced at pH 3, 5 and 7 to 
which excess ramipril was added. Solutions were left stirring for 1h before samples were 
filtered and prepared for HPLC analysis. 
Determination of ramipril ± HP-ȕ-CD binding constant and stoichiometry 
 In order to identify the binding constant and stoichiometry for drug-cyclodextrin 
complex, known amounts of ramipril were added to 4.8x10-3M solution of HP-ȕ-CD in water at 
increasing increments of 1.0x10-3M up to 1.0x10-2M. Temperature was maintained at 25°C 
and pH was recorded throughout. Conductometry readings were taken using a conductometer 
equipped with a probe containing 2 platinum electrodes (surface 1 cm2, separation distance 
of 1 cm) after each addition of drug. A graph of the conductance readings was produced. 
Stoichiometry and binding constant of the drug-cyclodextrin complex was calculated by 
plotting conductance against the molar ratio of cyclodextrin.  
Suspension approach to ramipril Fformulation 
Rheology  
 Ramipril suspensions containing 0.1-0.5%w/v (recommended concentration as 
suspending agent) of  Xantural® were prepared to study flow behaviour. Suspension rheology 
was investigated to provide information on flow properties by measuring suspension viscosity 
at different shear rates using a Brookfield DV ± I + Viscometer at shear rates of 0.08, 0.16, 
0.32, 0.83 and 1.67 reciprocal seconds  at 20°C. 
Investigation into the rate and volume of sedimentation 
 The theoretical rate and volume of sedimentation was calculated using Stokes 
equation. For investigation into the actual rate and volume of sedimentation, ramipril 
suspensions containing 0.1-0.5%w/v Xantural® were prepared and allowed to stand 
undisturbed for four weeks at 20°C. Actual sedimentation was obtained from the 
sedimentation volume. Studies were carried out on three different batches of the formulations. 
 
Particle size and investigation into Ostwald Ripening 
 Ramipril suspensions were produced in distilled water using Xantural® 180 at 
concentrations ranging between 0.1-0.5% w/v and particle size was measured using a 
Sympatec HELIOS/BF particle size analyser. The suspensions were heated and cooled 
repeatedly and particle size was measured after each cycle. Microscopic images were also 
recorded to document any crystal growth. Each cycle involved heating to 40°C for 24h  
followed by cooling to 4°C for 24h . Studies were carried out on three different batches of the 
formulations. 
Analysis of zeta potential 
 Ramipril suspensions (0.1-0.5%w/v Xantural® 180) were analysed using a zeta plus 
zeta potential analyser in conjunction with a BI-ZEL electrode assembly (Brookhaven 
Instruments). 100µl of the formulation was added to the cuvette containing approximately 
1.5ml of distilled water and zeta potential was recorded on three different batches of the same 
formulation. The values presented are the mean of the three measurements. 
Stability analysis 
 The conditions for stability testing were based on the guidelines set out in the ICH 
Harmonisation Guidelines Q1A(R2).(17) Stability investigations were carried out at 40°C and 
75% humidity for accelerated testing and 25°C and 60% humidity for long term stability testing. 
The final formulations were tested on a monthly basis and assessed quantitatively by HPLC 
and for pH. Formulations were also assessed qualitatively for colour changes and odour and 
suspensions were assessed for resuspendibility of any sediment. 
Assessment of absorption In Vitro 
Culture of Caco-2 cells for permeability assay  
 Caco-2 cells (passage 45) (A kind gift from Dr Andrew Collett and Dr Daniel Patten at 
the University of Huddersfield) were seeded at a density of 1.3x105 cells/cm2 onto permeability 
supports (Appelton Woods Ltd). Cells were cultured in an incubator (Sanyo) at 37°C in a 
humidified 5% CO2/95% air atmosphere. Media was changed every 2-3 days over a three 
week period. Trans-epithelial electronic resistance (TEER) measurements were taken 
following each media change and immediately before and after experiments using an EVOM 
± Epithelial Voltohmmeter (World Precision Instruments Ltd). Minimum TEER threshold of 
cm2 (before and after the experiment) was set as a standard to ensure monolayer 
integrity.  
Trans-epithelial flux of ramipril across Caco-2 monolayers 
 Culture media was removed and the monolayers were washed and incubated (pH 
range 6.7 - 7.8)  at 37°C for 30min with 2.5ml and 1.5ml of HBSS basolaterally and apically 
respectively. In each case, HBSS was then replaced in the apical compartment with 1.5ml of 
the optimised formulation to be tested. Monolayer containing transwells (not exposed to the 
drug) were used as controls.  200µl samples were then taken from the basolateral 
compartment at time points of 5, 10, 15, 20, 30, 60, 90, and 120min. 200µl of HBSS was added 
in each case to maintain volume of solution in the basolateral compartment which was 
accounted for in calculations. Samples were analysed via HPLC. All of the experiments were 
performed in triplicate and the level of transport was described as the percentage of drug 
arriving in the basolateral compartment. Following the production of a transport/time graph 
which displays the rate of drug transport form the apical to basolateral chamber of the 
permeability support over the time of the assay, Papp was calculated.(18) 
Genomic profiling of Caco-2 following in vitro absorption studies 
 Investigation into gene expression changes of Caco-2 cells following drug transport 
studies were intended to identify link between the predicted drug permeability and the 
expression of the genes which code for the intestinal transporters of ramipril. Microarray assay 
was performed on RNA samples collected from Caco-2 cells following trans-epithelial flux 
experiments on ramipril solutions developed using co-solvency and cyclodextrin approaches 
in addition to the suspension formulation.  These assays were carried out following the 
GLUHFWLRQV IRU$JLOHQW7HFKQRORJLHV¶RQH-colour microarray-based gene expression analysis 
low input quick amp labelling kit. In short, 1.5µl of 50ng total RNA was mixed with 2µl of spike 
mix (dilution 4), cDNA master mix (Agilent Technologies, Santa Clara, CA) was used to 
prepare cDNA for all samples ahead of labelling with cyanine 3-CTP (Cy3) in the labelling 
reaction. The labelled and amplified cRNA was then purified using RNeasy mini spin columns 
(Qiagen) and quantified using Nanodrop ND-1000 UV-VIS spectrophotometer 
(Thermoscientific, Wilmington, DE). All samples were then hybridised to Agilent 4x44K whole 
genome arrays for 17(h) at 65°C in a hybridisation oven (Sheldon manufacturer, Corneilus, 
OR). Following the hybridisation stage slides were washed using the gene expression wash 
buffer kit (Agilent Technologies, Santa Clara, CA) and acetonitrile. Scanning was carried out 
at using Agilent Scanner (Agilent Technologies, Santa Clara, CA) at a resolution of 50n. 
Feature Extraction software (V10.7, Santa Clara, CA) was implemented to examine the quality 
of the 16-bit TIFF images obtained by microarray scanning.  
 Statistical analysis was carried out using Significance Analysis of Microarrays (SAM) 
to identify statistically significant genes which demonstrated either a 2 fold up regulation in 
expression or a 2 fold down regulation in gene expression when compared to their expression 
levels in control populations. Delta values were selected so as that the median false discovery 
rate (FDR) was lower than 5%. These gene lists were then exported to EXCEL where the 
gene tables of SLC and ABC genes were prepared for data entry into the Kyoto Encyclopaedia 
of Genes and Genomes (KEGG) http://www.genome.jp/kegg/. (19) 
Assessment of absorption in vivo. 
 Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK) and was 
carried out in a designated establishment. Wistar rats with a body weight of approximately 
250g-300g were used. Prepared formulations were loaded into a 1ml syringe and administered 
via oral gavage. Dosing was calculated depending upon the weight of each individual animal 
(5mg/kg) and formulations were diluted in water. Following dosing, an additional 1ml of H2O 
was administered to rinse in the formulations. Blood samples (45µl) were taken via tail bleeds 
at 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h and 4h time points following administration. 
Plasma was extracted from blood samples by centrifugation at 2800 x g for 10min. The plasma 
samples were then diluted 1:5 in mobile phase and analysed using HPLC. 
  
 
 
 
 
 
 
 
Results and Discussion 
 The first phase of product development was focused on excipient selection and 
process optimisation. One of the main considerations was to ensure that the formulations were 
developed with  minimal number of excipients at their lowest possible concentration.  The first 
approach towards the development of oral liquid solution was studied using acetic acid as a 
co-solvent to enhance the apparent solubility of ramipril.  
Co-solvent approach to the solubilisation of ramipril 
 Initial investigations were focussed on solubility profiling of ramipril following the 
addition of a range of different concentrations of acetic acid in water. Acetic acid-water co 
solvents were prepared in the concentration range between 0.01 ± 4%v/v of acetic acid and 
the solubility of ramipril was assessed using HPLC. The various co solvent mixtures were also 
assessed for their organoleptic properties such as colour and smell as well as their final pH. 
All of the co-solvent solutions achieved complete solubilisation of ramipril to form colourless 
solutions. The pH of the solutions became less acidic as the acetic acid concentration 
decreased. For instance, the pH of the lowest acetic acid concentration (0.01%v/v) was 3.8 
and the highest acetic acid concentration (4.0%v/v) was 2.4. For all of the solutions, the smell 
of  acetic acid was negligible.  
  Ramipril was solubilised utilising acetic acid and distilled water as a co-solvent system 
even at acetic acid concentrations as low as 0.01% (v/v). This lends itself to use in the 
production of an oral liquid dosage form as the low levels of co-solvent are ideal. This is of 
particular importance when targeting paediatrics and especially so with acetic acid owing to 
unpleasant taste and smell being potentially significant factors. Additionally, low 
concentrations of acetic acid minimises requirements for taste and odour masking.  The 
concentration of acetic acid solution deemed most suitable for use in the solubilisation of 
ramipril was 0.02% (v/v). This was the lowest concentration at which  instantaneous 
solubilisation was achieved at the same time  yielding a suitable pH (3.7), colour (clear) and 
odour (odourless).  
The final formulation composition and process consisted of addition of 1mg/ml of ramipril into 
0.02% v/v acetic acid - water cosolvent  mixture under stirring to ensure complete solubilisation 
and homogeneity. This was followed by the addition of other excipients in the following order: 
ascorbic (0.1mg/ml; antioxidant), xylitol (200mg/ml; sweetener), parabens (propyl -0.1mg/ml, 
butyl ± 0.06mg/ml; preservative) and finally orange flavour (0.1%v/v) (Table 1).    
Cyclodextrin approach to solubilising ramipril 
Cyclodextrin based liquid dosage forms were investigated as they provide dual advantage 
including enhancement of apparent drug solubility as well as taste masking through drug 
encapsulation.  
Phase Solubility  
 Phase solubility profile of ramipril in the presence of various concentrations HP-ȕ-CD 
was studied to identify the stoichiometry during drug-complex formation. The results showed 
that the phase solubility profile for ramipril complexed with HP-ȕ-CD was that of the AL type 
(Figure 1) which demonstrates a linear relationship between the increase in drug solubilisation  
with the increase in cyclodextrin concentration. This is particularly useful as the linear 
relationship allows for close estimation of the concentration of cyclodextrin needed to 
solubilise a chosen concentration of ramipril.  Using the gradient from the equation for the line 
it can be estimated that there was a 1:1 molar  binding ratio between ramipril and cyclodextrin 
molecules. In the current study, as the target dose of  ramipril in the formulation is 1mg/ml 
(which equates to 0.24mM), it can be estimated that 0.24mM of cyclodextrin will be required 
to solubilise the drug (0.24mM equates to 3.5mg/ml).  
 Drug solubility following complexation with cyclodextrin has been show to vary upon 
modification of the pH of a system. This possibly occurs as a result of alteration to the 
complexation constant with solubility increases resulting in an increase in complexation 
constant.(20) As shown  in Figure 2, the optimum pH for the solubilisation of ramipril using 
HP-ȕ-CD was  3 with both pH 5 and 7 showing reduced solubilisation. These differences in 
solubilisation at different pH values could possibly be due to the existence of either ionised or 
un ionised form of the drug.  The concentration of ionised form of ramipril is higher at pH close 
to neutral and previous research has shown that the degree of complex formation for  HP-ȕ-
CD is lowered for  ionised molecules when compared with their uncharged form.(21) The 
negative charge present following ionisation of ramipril could result in repulsive forces between 
cyclodextrin and drug molecules and between drug molecules leading to a reduction in 
complexation. 
Following the evaluation of drug-cyclodextrin molar ratio and the impact of pH on the resultant 
complex, the production of the formulation consisted of the preparation of cyclodextrin solution 
by dissolving 3.51mg/mL of HP-ȕ-CD in distilled water. The next stage included the addition 
of 1mg/ml ramipril under stirring until it was completely dissolved. Following this, the other 
excipients were added in the following order: ascorbic (0.1mg/ml; antioxidant), xylitol 
(200mg/ml; sweetener), parabens (propyl - 0.1mg/ml, butyl ± 0.06mg/ml; preservative) and 
finally orange flavour (0.1%v/v) (Table 1). The pH of the final formulation was pH 3.75. 
 
 
 
 
 
Suspension formulation development 
The development of a suspension requires selection and optimisation of a suitable 
concentration of suspending agent along with the assessment of sedimentation rate and re- 
suspendibility of the formulation. 
Suspension Rheology, rate and volume of sedimentation 
 The first sets of investigations included determination of flow properties of the 
suspending medium using shear rate response to changes in shear stress which was 
evaluated using a viscometer. Five different suspensions were produced using different 
concentrations of Xantural® ranging between 0.1-0.5%w/v (recommended concentration range 
as suspending agent) and analysed at five different shear stresses at 20°C. The results (Figure 
3) showed that Xantural® 180 displayed pseudoplastic properties which provide desirable flow 
properties with the largest change in apparent viscosity being observed for the highest 
concentration of Xantural® (0.5% v/v).  These studies were followed up by assessing the 
theoretical rate of sedimentation for ramipril in Xantural® using 6WRNHV¶ HTXDWLRQ and 
experiments to confirm the rate and volume of sedimentation. Suspensions with the different 
concentrations of Xantural® were prepared and inspected at various time points over a four 
week period. The results showed (data not included) that there was no sedimentation 
observed at any of the time points for the entire range of concentrations investigated and the 
zeta potential was within +/-25mV range. Similarly, particles in a suspension can also give 
rise to ostwald ripening or crystal growth. Particle size is directly related to the rate of 
sedimentation, an increase in particle size via Ostwald ripening will lead to destabilisation of 
a stable suspension. Particle size measurements were performed after heating and cooling 
cycles to investigate Ostwald ripening. The findings from these studies (data not included) 
showed that there was no increase in particle size when subjected to temperature changes 
between 4 and 40OC. 
The final composition and process for preparing ramipril suspensions included production of   
0.1%w/v Xantural® 180 solution, into which 1mg/ml ramipril was then added slowly with 
vigorous stirring to ensure it is evenly distributed throughout the vehicle. This stage was 
followed by the addition of sodium meta bisulphate (10mg/ml; antioxidant), xylitol (400mg/ml; 
sweetener), sodium benzoate (5mg/ml; preservative) and strawberry flavour (0.2%v/v).   The 
pH of the final formulation was 4.25.  
 For all the optimised dosage forms, it was inevitable to include lowest possible 
concentration of preservatives as the primary vehicle is water and supports microbial growth. 
Taste assessment studies including indirect methods to evaluate taste such as drug release 
and dissolution testing (which are generally used for taste masked drug and require validation 
through direct taste assessment studies) have not been included as there are no taste related 
issues reported for ramipril. Indeed the inclusion of sweeteners and flavours in all the different 
dosage forms as well the formulation of drug complexed cyclodextrin liquid will ensure patient 
acceptability and compliance without any concerns for palatability. Following formulation 
profiling together with investigation of optimal process and excipient parameters that meet the 
TPPP, the next stage of evaluation consisted of stability testing and subsequent drug 
absorption and genomic analysis.  
Stability Analysis 
 Over the course of six month for stability testing at accelerated conditions at 40°C and 
75% relative humidity, the drug content of the formulations fell below 95% of the starting dose 
indicating that the formulations failed to display adequate stability in accordance with ICH 
guidelines. pH remained constant for the duration of the stability testing in accelerated 
conditions. At long term conditions at 25°C and 60% relative humidity, drug content for all of 
the formulations remained >95% of the starting dose and pH remained constant for the 
duration of the 12 month testing period. Additionally, all formulations maintained their 
aesthetics. Suspension formulations did not display any sedimentation throughout the study 
suggesting that the inherent limitations of physical instability experienced by many suspension 
based formulations was successfully overcome and that sedimentation was totally prevented.  
 Degradation seen under accelerated conditions is possibly as a result of the elevated 
temperature. Ramipril diketopiperazine (DKP) degradate is the primary degradation 
compound for ramipril. Degradation occurs through intramolecular condensation with the 
formation of a second amide bond.(22) The pH of the formulation in both accelerated and long 
term conditions did not change beyond the acceptance levels for the formulation. Additionally, 
the appearance and odour of the formulations remained acceptable for the duration of the 
stability testing in both long term and accelerated conditions. The results show that 
formulations do not require refrigeration but would require storage in a cool location (<25°C).  
 In Vitro and In Vivo Evaluation of Ramipril Formulations 
Assessment of Absorption In Vitro 
 Permeability coefficient or apparent permeability of a molecule (Papp) is considered a 
reliable indicator for the expected in vivo drug absorption (Fraction Absorbed (fa)). It is 
generally accepted that completely absorbed drugs have Papp >1x10-6cm/s (LogPapp > -6) and 
incompletely or poorly absorbed drugs have Papp <1x10-6cm/s (LogPapp < -6).(23)  
 Following permeability experiments, samples were analysed via HPLC and the findings 
from which were plotted to reveal the percentage of drug that was transported from the apical 
to the basolateral compartment of the transwell as a factor of time. TEER values were 
measured before and after the permeability experiments for each transwell to ensure the 
integrity of the monolayer. In all cases the TEER remained above an acceptable level of 35 
cm2.  
  Previous investigations into Papp reported permeability coefficients ranging from 
approximately 5x10-8 to 5x10-5cm/s. Permeability coefficients for ramipril formulations in the 
current investigations were in keeping with these findings and demonstrated  limited 
absorption of the drug for all the different formulations (Figure 5)(23).  
Genomic Assessment of Caco-2 Following In Vitro Absorption Assay 
 Investigation into gene expression changes of Caco-2 cells following drug transport 
studies were carried out to identify link between the predicted drug permeability and the 
expression of the genes which code for the intestinal transporter of  ramipril (SLC15A1 and 
SLC15A2).(5) The expression patterns for Caco-2 cells in their basal state were used as a 
control and compared to cells which had been exposed to ramipril formulations. 
 The genes from the solute carrier transporters (SLC) superfamily for which a significant 
change in gene expression was seen were used in KEGG pathway identification. For the 
ramipril solution produced using cyclodextrin as a solubiliser there was significant effect on 10 
genes in the SLC family for which a >2 fold up regulation was observed. For the ramipril co 
solvent solution, there was significant effect on 26 genes in the SLC family. The ramipril 
suspension caused significant up regulation of 29 genes in the SLC family.   
 KEGG pathway analysis of the significantly up regulated SLC transporter genes 
returned pathway information for SLC16A10 which codes for TAT1. TAT1 is present in the 
basolateral membrane of intestinal epithelial cells and transports neutral amino acids into and 
out of the blood.(24,25) SLC16A10 was seen to be significantly up regulated for all of the 
ramipril formulations. There were significant expressional changes for numerous SLC 
transporters in the protein absorption pathway across the intestinal epithelial but not SLC15A1, 
the transporter for which ramipril is a substrate. SLC15A1 codes for the PEPT1 transporter 
which is present in the apical membrane of intestinal epithelial cells and responsible for the 
absorption of small peptides.(26,27) The pathways and proteins, for which the SLC genes 
displayed significant modification in gene expression could be linked to ramipril absorption as 
TAT1 similar to PETP1 is involved in protein absorption pathways. The changes in expression 
levels could have resulted following interaction with the API in the formulations, however the 
excipients present could have also had an effect. This would account for up regulation in genes 
coding for transporter proteins which would not have necessarily been anticipated as a result 
of interaction with the API alone. This lends strength to the recently developing ideology that 
excipients potentially possess biological activity and are not inactive ingredients.(28,29) 
Assessment of Absorption In Vivo 
 The plasma concentration-time profile for the formulations for in vivo absorption is 
shown in Figure 5. From the plasma concentration-time profile, values for area under the curve 
(AUC), CMAX and TMAX were determined and are shown in Table 2. Ramipril AUC values were 
within the anticipated range as its bioavailability is known to be highly variable between 
individuals with reports showing variation ranging between 6-60%. (4) Ramipril showed a CMAX 
of 10.48 µg/mL for the solution produced using  co-solvent, 13.04µg/ml for the ramipril 
suspension and 29.58µg/mL for the ramipril solution produced using cyclodextrin as a 
solubiliser. 
 The findings for CMAX and TMAX reveal interesting findings; ramipril solution produced 
using co-solvent and the ramipril suspension showed TMAX at 2.5h after administration. 
However, ramipril solution produced using cyclodextrin showed a much earlier TMAX occurring 
only 0.75h following administration. As the only formulation component which is unique to the 
ramipril solution produced using cyclodextrins as a solubiliser is the HP-ȕ-CD it is possible 
that this excipient is responsible for the earlier TMAX and higher CMAX. There is evidence that 
HP-ȕ-CD decreases GI transit time in rats thus shortening the time taken for the drug to reach 
the site of absorption.(30) As ramipril is absorbed mainly in the Ileum, this would result in the 
formulation reaching the site of absorption more rapidly. Ordinarily, a decrease in intestinal 
residence time would see a decrease in absorption due to a shorter absorption window 
however cyclodextrins have the ability to improve drug absorption. It is generally recognized 
that cyclodextrins act as true carriers by keeping the hydrophobic drug molecules in solution 
and deliver them to the surface of the biological membrane. The relatively lipophilic membrane 
has low affinity for the hydrophilic cyclodextrin molecules and therefore they remain in the 
aqueous membrane exterior, e.g. the aqueous vehicle system or GI fluid. Conventional 
penetration enhancers, such as alcohols and fatty acids, disrupt the lipid layers of the 
biological barrier however, cyclodextrins, on the other hand, act as penetration enhancers by 
increasing drug availability at the surface of the biological barrier.  
Conclusions 
 Oral liquid ramipril formulations targeting the paediatric population were produced 
addressing the needs outlined in EMA/480197/2010. The current study has outlined for the 
first time the different oral liquid formulations of ramipril that can be produced without the need 
for inclusion of high concentration of excipients that are not recommended for use in paediatric 
formulations. The results provide the formulator with the option of developing either a solution 
or suspension based formulation which has a shelf life of twelve months. Biopharmaceutical 
evaluation of the formulated products has shown that they exhibit similar permeability as well 
as pharmacokinetic profile as reported in clinical literature.  Results from these investigations 
provide the platform to formulate better medicines for children using simple, cost effective and 
scalable processing parameters.   
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Figure 1 - Phase solubility profile for Ramipril complexed with HP-ȕ-CD. Six concentrations of cyclodextrin were 
produced in distilled water from 1.2mM to 3.75µM using serial dilution. To these excess Ramipril was added. 
Solutions were left stirring for 1 hour before samples were filtered and prepared for HPLC analysis (n=3). 
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 Figure 2 - Effect of pH on Ramipril solubility in the presence of HP-ȕ-CD. Six concentrations of cyclodextrin were 
produced in distilled water from 1.2mM to 3.75µM using serial dilution. These were produced in solutions of pH 3, 
5 and 7 and to these excess Ramipril was added. Solutions were left stirring for 1 hour before samples were filtered 
and prepared for HPLC analysis (n=3). 
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 Figure 3 - Suspension viscosity under variable shear stress in Ramipril suspensions. Ramipril suspensions (n=3) 
in concentrations of Xanatural from 0.1-0.5%w/v were prepared and suspension Rheology was investigated to 
provide information on flow properties by measuring suspension viscosity at different shear rates using a Brookfield 
DV ± I + Viscometer at shear rates of 0.08, 0.16, 0.32, 0.83 and 1.67 reciprocal seconds.. As expected all 
concentrations of Xanatural 180 displayed pseudoplastic flow with the viscosity at each measurement point being 
proportional to the concentration of Xanatural 180 present in the solution.   
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Gum)
0.1% Xanatural
0.2% Xanatural
0.3% Xanatural
0.4% Xanatural
0.5% Xanatural
 Figure 4 - Apparent permeability values for Ramipril formulations. It is generally accepted that completely absorbed 
drugs have Papp >1x10-6cm/s. (LogPapp > -6) and incompletely or poorly absorbed drugs have Papp <1x10-
6cm/s. (LogPapp < -6). Permeability coefficients for Ramipril formulations are in keeping with these values, Ramipril 
has limited absorption and this is supported with all of the Ramipril formulations displaying LogPapp < -6cm/s (n=3).  
  
 
Figure 5 - Plasma Concentrations Following Oral Administration (n=3). Ramipril showed a CMAX range of 10.48 
µg/mL for the Ramipril solution produced using a co-solvent, 13.04µg/ml for the Ramipril Suspension and 
29.58µg/mL for the Ramipril solution produced using cyclodextrin as a solubiliser. Ramipril solution produced using 
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a co-solvent and the Ramipril suspension of TMAX 2.5h. The Ramipril solution produced using cyclodextrin however 
shows a much earlier TMAX occurring only 0.75h following administration. 
 
 
